When to treat myelodysplastic syndromes.

Mojtaba Akhtari

Research output: Contribution to journalArticle

Abstract

The myelodysplastic syndromes represent a heterogeneous series of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and a variable risk of progression to acute myeloid leukemia. These syndromes have a complex pathobiology, and ineffective hematopoiesis is a well-recognized feature of all of them. Normal blood cell maturation, differentiation, function, and survival are impaired, and these abnormalities contribute to the development of peripheral blood pancytopenia. The majority of patients succumb to complications of either bone marrow failure or leukemic progression. The fact that the majority of patients are elderly and have other comorbidities complicates therapeutic decision making and necessitates the development of individualized treatment strategies.

Original languageEnglish (US)
Pages (from-to)480-486
Number of pages7
JournalOncology (Williston Park, N.Y.)
Volume25
Issue number6
StatePublished - May 2011

Fingerprint

Myelodysplastic Syndromes
Hematopoiesis
Pancytopenia
Hematologic Neoplasms
Acute Myeloid Leukemia
Comorbidity
Cell Differentiation
Blood Cells
Decision Making
Bone Marrow
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

When to treat myelodysplastic syndromes. / Akhtari, Mojtaba.

In: Oncology (Williston Park, N.Y.), Vol. 25, No. 6, 05.2011, p. 480-486.

Research output: Contribution to journalArticle

Akhtari, M 2011, 'When to treat myelodysplastic syndromes.', Oncology (Williston Park, N.Y.), vol. 25, no. 6, pp. 480-486.
Akhtari, Mojtaba. / When to treat myelodysplastic syndromes. In: Oncology (Williston Park, N.Y.). 2011 ; Vol. 25, No. 6. pp. 480-486.
@article{770cd4c34399422eaf3b0950390c2830,
title = "When to treat myelodysplastic syndromes.",
abstract = "The myelodysplastic syndromes represent a heterogeneous series of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and a variable risk of progression to acute myeloid leukemia. These syndromes have a complex pathobiology, and ineffective hematopoiesis is a well-recognized feature of all of them. Normal blood cell maturation, differentiation, function, and survival are impaired, and these abnormalities contribute to the development of peripheral blood pancytopenia. The majority of patients succumb to complications of either bone marrow failure or leukemic progression. The fact that the majority of patients are elderly and have other comorbidities complicates therapeutic decision making and necessitates the development of individualized treatment strategies.",
author = "Mojtaba Akhtari",
year = "2011",
month = "5",
language = "English (US)",
volume = "25",
pages = "480--486",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "6",

}

TY - JOUR

T1 - When to treat myelodysplastic syndromes.

AU - Akhtari, Mojtaba

PY - 2011/5

Y1 - 2011/5

N2 - The myelodysplastic syndromes represent a heterogeneous series of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and a variable risk of progression to acute myeloid leukemia. These syndromes have a complex pathobiology, and ineffective hematopoiesis is a well-recognized feature of all of them. Normal blood cell maturation, differentiation, function, and survival are impaired, and these abnormalities contribute to the development of peripheral blood pancytopenia. The majority of patients succumb to complications of either bone marrow failure or leukemic progression. The fact that the majority of patients are elderly and have other comorbidities complicates therapeutic decision making and necessitates the development of individualized treatment strategies.

AB - The myelodysplastic syndromes represent a heterogeneous series of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and a variable risk of progression to acute myeloid leukemia. These syndromes have a complex pathobiology, and ineffective hematopoiesis is a well-recognized feature of all of them. Normal blood cell maturation, differentiation, function, and survival are impaired, and these abnormalities contribute to the development of peripheral blood pancytopenia. The majority of patients succumb to complications of either bone marrow failure or leukemic progression. The fact that the majority of patients are elderly and have other comorbidities complicates therapeutic decision making and necessitates the development of individualized treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=79960696518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960696518&partnerID=8YFLogxK

M3 - Article

C2 - 21717901

VL - 25

SP - 480

EP - 486

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 6

ER -